Mucosal Vaccine Adjuvants Update

Overview

Journal Clin Exp Vaccine Res

Date 2013 Apr 19

PMID 23596577

Citations 62

Authors

Joon Haeng Rhee

Shee Eun Lee

Soo Young Kim

Affiliations

Soon will be listed here.

Abstract

Mucosal vaccination, capable of inducing protective immune responses both in the mucosal and systemic immune compartments, has many advantages and is regarded as a blue ocean in the vaccine industry. Mucosal vaccines can offer lower costs, better accessability, needle-free delivery, and higher capacity of mass immunizations during pandemics. However, only very limited number of mucosal vaccines was approved for human use in the market yet. Generally, induction of immune responses following mucosal immunization requires the co-administration of appropriate adjuvants that can initiate and support the effective collaboration between innate and adaptive immunity. Classically, adjuvant researches were rather empirical than keenly scientific. However, during last several years, fundamental scientific achievements in innate immunity have been translated into the development of new mucosal adjuvants. This review focuses on recent developments in the concepts of adjuvants and innate immunity, mucosal immunity with special interest of vaccine development, and basic and applied researches in mucosal adjuvant.

Citing Articles

Induction of protective immune responses at respiratory mucosal sites.

Park S, Wiest M, Yan V, Wong P, Schotsaert M Hum Vaccin Immunother. 2024; 20(1):2368288.

PMID: 38953250 PMC: 11221474. DOI: 10.1080/21645515.2024.2368288.

Polymeric Caffeic Acid Acts as an Antigen Delivery Carrier for Mucosal Vaccine Formulation by Forming a Complex with an Antigenic Protein.

Tada R, Nagai Y, Ogasawara M, Saito M, Ohshima A, Yamanaka D Vaccines (Basel). 2024; 12(5).

PMID: 38793700 PMC: 11126084. DOI: 10.3390/vaccines12050449.

Vaccine Strategies to Elicit Mucosal Immunity.

Song Y, Mehl F, Zeichner S Vaccines (Basel). 2024; 12(2.

PMID: 38400174 PMC: 10892965. DOI: 10.3390/vaccines12020191.

Expressing Murine Rotavirus VP8 and Mucosal Adjuvants Induce Virus-Specific Immune Responses.

Gilfillan D, Vilander A, Pan M, Goh Y, OFlaherty S, Feng N Vaccines (Basel). 2023; 11(12).

PMID: 38140179 PMC: 10747613. DOI: 10.3390/vaccines11121774.

Recent progress in application of nanovaccines for enhancing mucosal immune responses.

Du G, Qin M, Sun X Acta Pharm Sin B. 2023; 13(6):2334-2345.

PMID: 37425056 PMC: 10326163. DOI: 10.1016/j.apsb.2022.08.010.

References

Eriksson K, Holmgren J . Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol. 2002; 14(5):666-72. DOI: 10.1016/s0952-7915(02)00384-9. View

Varol C, Vallon-Eberhard A, Elinav E, Aychek T, Shapira Y, Luche H . Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity. 2009; 31(3):502-12. DOI: 10.1016/j.immuni.2009.06.025. View

Pesce I, Monaci E, Muzzi A, Tritto E, Tavarini S, Nuti S . Intranasal administration of CpG induces a rapid and transient cytokine response followed by dendritic and natural killer cell activation and recruitment in the mouse lung. J Innate Immun. 2010; 2(2):144-59. DOI: 10.1159/000254948. View

Fritz J, Ferrero R, Philpott D, Girardin S . Nod-like proteins in immunity, inflammation and disease. Nat Immunol. 2006; 7(12):1250-7. DOI: 10.1038/ni1412. View

Bracho G, Lastre M, Del Campo J, Zayas C, Gonzalez D, Gil D . Proteoliposome derived cochleate as novel adjuvant. Vaccine. 2006; 24 Suppl 2:S2-30-1. DOI: 10.1016/j.vaccine.2005.01.108. View

Raghavan S, Ostberg A, Flach C, Ekman A, Blomquist M, Czerkinsky C . Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Infect Immun. 2010; 78(10):4251-60. PMC: 2950356. DOI: 10.1128/IAI.00536-10. View

McKee A, Munks M, Marrack P . How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007; 27(5):687-90. DOI: 10.1016/j.immuni.2007.11.003. View

Yamamoto M, Pascual D, Kiyono H . M cell-targeted mucosal vaccine strategies. Curr Top Microbiol Immunol. 2011; 354:39-52. PMC: 7393565. DOI: 10.1007/82_2011_134. View

Noda K, Kodama S, Umemoto S, Abe N, Hirano T, Suzuki M . Nasal vaccination with P6 outer membrane protein and alpha-galactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx. Vaccine. 2010; 28(31):5068-74. DOI: 10.1016/j.vaccine.2010.05.005. View

10.

Sanchez J, Wallerstrom G, Fredriksson M, Angstrom J, Holmgren J . Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination. J Biol Chem. 2002; 277(36):33369-77. DOI: 10.1074/jbc.M112337200. View

11.

Hornung V, Bauernfeind F, Halle A, Samstad E, Kono H, Rock K . Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008; 9(8):847-56. PMC: 2834784. DOI: 10.1038/ni.1631. View

12.

Hu K, Lovgren-Bengtsson K, Morein B . Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev. 2001; 51(1-3):149-59. DOI: 10.1016/s0169-409x(01)00165-x. View

13.

GLENNY A . INSOLUBLE PRECIPITATES IN DIPHTHERIA AND TETANUS IMMUNIZATION. Br Med J. 2010; 2(3632):244-5. PMC: 2450349. DOI: 10.1136/bmj.2.3632.244. View

14.

Chen W, KuoLee R, Yan H . The potential of 3',5'-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant. Vaccine. 2010; 28(18):3080-5. DOI: 10.1016/j.vaccine.2010.02.081. View

15.

Lee S, Kim S, Jeong B, Kim Y, Bae S, Ahn O . A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun. 2005; 74(1):694-702. PMC: 1346682. DOI: 10.1128/IAI.74.1.694-702.2006. View

16.

Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

17.

Pizza M, Giuliani M, Fontana M, Monaci E, Douce G, Dougan G . Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine. 2001; 19(17-19):2534-41. DOI: 10.1016/s0264-410x(00)00553-3. View

18.

de Haan L, Hirst T . Cholera toxin and related enterotoxins: a cell biological and immunological perspective. J Nat Toxins. 2000; 9(3):281-97. View

19.

McGowen A, Hale L, Shelburne C, Abraham S, Staats H . The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine. 2009; 27(27):3544-52. PMC: 2743390. DOI: 10.1016/j.vaccine.2009.03.069. View

20.

Holmgren J, Czerkinsky C, Eriksson K, Mharandi A . Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine. 2003; 21 Suppl 2:S89-95. DOI: 10.1016/s0264-410x(03)00206-8. View